Beryl Drugs Limited has officially confirmed the completion of dispatch for its Extraordinary General Meeting (EOGM) notice to eligible shareholders. The company filed a notification with BSE on April 3, 2026, confirming that newspaper advertisements have been published to notify shareholders about the completion of notice dispatch along with e-voting information and record date details.

EOGM Schedule and Voting Framework

The EOGM is scheduled for Monday, May 11, 2026, at 11:00 AM at Kanchan Palace, Community Hall, Nipania Ring Road, Indore (M.P.). The company has established a comprehensive remote e-voting framework under Section 108 of the Companies Act, 2013, providing shareholders with electronic voting facilities.

Shareholders holding shares in either physical or dematerialized form as on the cut-off date of May 4, 2026, will be entitled to participate in remote e-voting or vote at the EOGM venue.

Key Agenda Items and Director Appointments

The EOGM will address three special business items focusing on director appointments and corporate governance matters. The meeting will regularize Mr. Shailendra Pathak's appointment as Whole Time Director, who was initially appointed as Additional Director on January 3, 2026.

Mrs. Neha Sarda will be appointed as Non-Executive Independent Director, bringing her expertise as a qualified Company Secretary with over 8 years of experience in corporate compliance and Company Law matters.

Related Party Transaction Approval

The EOGM will seek approval for material Related Party Transactions with M/s. Aminova Infusions P. Ltd., where Mr. Shailendra Pathak serves as a director holding 50% equity. This transaction requires shareholder approval as it represents approximately 13.30% of the company's annual consolidated turnover.

The transaction involves Aminova distributing Beryl Drugs' PP Bottle and FFS products in Maharashtra, Gujarat, and international markets, leveraging Mr. Pathak's pharmaceutical industry expertise.

Regulatory Compliance and Communication

The company's latest BSE filing demonstrates its commitment to maintaining transparent communication with stakeholders. Managing Director Sanjay Sethi (DIN: 00090277) signed the official notification confirming the completion of notice dispatch through newspaper advertisements.

The e-voting results will be announced after the EOGM, with the Scrutinizer's Report being placed on the company's website. The comprehensive regulatory compliance framework ensures all shareholders can participate effectively in the decision-making process while strengthening corporate governance standards.

Beryl Drugs Limited has announced that its promoter and director Mr. Sudhir Sethi has acquired additional equity shares in the company through market transactions. The latest acquisition was disclosed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, demonstrating continued regulatory compliance by the pharmaceutical company.

Latest Share Acquisition Details

The most recent transaction involved the acquisition of 7500 equity shares on 24-03-2026, representing 0.14% of the company's total share capital. The acquisition was executed through market transactions on BSE, with a total transaction value of ₹1,57,441, showing sustained investment by the promoter in the company's prospects.

Updated Shareholding Pattern

Following the latest acquisition, Mr. Sudhir Sethi's shareholding in Beryl Drugs Limited has increased significantly. His total holding has grown from 4,86,483 shares to 4,93,983 shares, reflecting his continued confidence in the company's growth trajectory.

SEBI Regulatory Compliance

The disclosure was made under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, with Mr. Sudhir Sethi identified as a Promoter and Director (DIN: 00090172). The company submitted the required disclosure to BSE Limited on 25-03-2026, ensuring transparency in insider trading activities. Managing Director Sanjay Sethi (DIN: 00090277) submitted the disclosure on behalf of the company.

Company Information

Beryl Drugs Limited, incorporated in 1993 and headquartered in Indore, Madhya Pradesh, continues to maintain its commitment to regulatory compliance and corporate governance standards. The company's registered office is located at Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.), with CIN: L02423MP1993PLC007840.

The disclosure demonstrates the company's adherence to SEBI regulations regarding insider trading requirements for promoters and directors. The acquisition reflects positive sentiment from the promoter group regarding the company's future prospects in the pharmaceutical sector.